Risk stratification of patients with chronic heart failure using cardiac iodine-123 metaiodobenzylguanidine imaging: incremental prognostic value over right ventricular ejection fraction

Shunsuke Tamaki1*, Takahisa Yamada1, Takashi Morita1, Yoshio Furukawa1, Yusuke Iwasaki1, Masato Kawasaki1, Atsushi Kikuchi1, Takumi Kondo1, Tsutomu Kawai1, Satoshi Takahashi1, Masashi Ishimi1, Hideyuki Haku1, Tatsuhisa Ozaki1, Yoshihiro Sato1, Masahiro Seo1, Yasushi Sakata2 and Masatake Fukunami1

1Division of Cardiology, Osaka General Medical Center, Osaka, Japan; 2Division of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan

Abstract

Aims Right ventricular (RV) systolic dysfunction has been shown to be an independent predictor of clinical outcome in patients with chronic heart failure (CHF), and cardiac metaiodobenzylguanidine (MIBG) imaging also provides prognostic information. We aimed to evaluate the long-term predictive value of combining RV systolic dysfunction and abnormal findings of cardiac MIBG imaging on outcome in CHF patients.

Methods and results We enrolled 63 CHF outpatients with left ventricular ejection fraction (EF) < 40% in a prospective cohort study. At entry, RVEF was measured by radionuclide angiography. Furthermore, cardiac MIBG imaging was performed, and the cardiac MIBG washout rate (WR) was calculated. Reduced RVEF was defined as ≤ 37%, and abnormal WR was defined as > 27%. The study endpoint was unplanned hospitalization for worsening heart failure (WHF) and cardiac death. During a follow-up period of 8.9 ± 4.3 years, 19 of 63 patients had unplanned hospitalization for WHF, and 19 of 63 patients had cardiac death. In multivariate analysis, both WR and RVEF were independent predictors of unplanned WHF hospitalization, while WR was also an independent predictor of cardiac death. A risk-stratification model based on independent predictors of unplanned WHF hospitalization separated the patients into those with low (absence of the predictors), intermediate (one of the predictors), and high (two or more of the predictors) risk of unplanned WHF hospitalization (P < 0.0001) or cardiac death (P = 0.0113).

Conclusions Cardiac MIBG imaging provides incremental value when it is used along with RV systolic dysfunction to predict clinical outcome in patients with CHF.

Keywords Chronic heart failure; Reduced left ventricular ejection fraction; Prognosis; Cardiac metaiodobenzylguanidine imaging; Right ventricular systolic function; Nuclear cardiology

Received: 28 February 2015; Revised: 24 June 2015; Accepted: 9 July 2015

Introduction

Chronic heart failure (CHF) is an increasing socioeconomic burden on health-care systems, and hospitalizations due to heart failure make a significant contribution to the overall cost.1,2 Therefore, reliable risk stratification to identify CHF patients at risk of admission for worsening heart failure (WHF) is of great importance. Previous studies demonstrated that right ventricular (RV) systolic dysfunction predicts poor prognosis in CHF patients.3-6 In addition, cardiac iodine-123 (I-123) metaiodobenzylguanidine (MIBG) imaging also predicts poor outcome in CHF patients.7-11 However, little is known about the predictive value of combining RV systolic dysfunction and MIBG imaging on long-term outcome in CHF patients.
Aims

The aim of the current study was to investigate whether cardiac I-123 MIBG imaging provides additional prognostic information over RV systolic dysfunction in patients with CHF.

Methods

Patients

Sixty-three CHF outpatients with radionuclide left ventricular (LV) ejection fraction (EF) <40% were enrolled in a prospective cohort study. CHF was defined according to Framingham criteria. Patients were required to be stable for ≥3 months on conventional therapy. Patients with significant renal failure (serum creatinine >3.0 mg/dL), insulin-dependent diabetes mellitus, or autonomic neuropathy were excluded. None had had implantable cardioverter defibrillators, biventricular pacemakers, or biventricular defibrillators at enrollment. At entry, radionuclide angiography, cardiac MIBG imaging, and echocardiography were performed; and a venous blood sample was drawn. All patients gave written informed consent. The study complied with the Declaration of Helsinki and was approved by our institutional review committee. The primary endpoint of this study was unplanned hospitalization for WHF. Cardiac death was the other study endpoint.

Radionuclide angiography

Patients underwent electrocardiogram-gated blood-pool scintigraphy with a conventional rotating gamma camera (Prism 2000, Picker, Bedford, OH, USA). Patients were given 740 MBq of technetium-99m-labelled human serum albumin (Nihon Medi-Physics, Nishinomiya, Japan). Reduced RVEF was defined as ≤37%.6

Cardiac MIBG imaging

Myocardial imaging with I-123 MIBG (Daiichi Radioisotope Laboratory, Tokyo, Japan) was performed with the same gamma camera as that used for radionuclide angiography. A 111 MBq dose of I-123 MIBG was injected intravenously at rest after an overnight fast. Initial and delayed image acquisitions were performed in the anterior chest view at 20 and 200 min after isotope injection. The heart-to-mediastinum ratio and the cardiac MIBG washout rate (WR) were calculated; an abnormal WR was defined as >27%.8

Echocardiography

Two-dimensional echocardiography was performed to measure LV end-diastolic and end-systolic dimensions and left atrial dimension, and the severity of mitral regurgitation (MR) was graded as previously described.8,13

Statistics

Data are presented as the mean ± SD. A Student’s t-test and Fisher’s exact test were used to compare differences in continuous and discrete variables, respectively. The prognostic value of baseline characteristics was assessed with a Cox proportional hazards regression analysis. Event-free survival rates were calculated using the Kaplan–Meier method, and the differences in survival rates were compared between groups with the log-rank test. A P value <0.05 was considered significant.

Results

Comparison of baseline characteristics

During a follow-up period of 8.9 ± 4.3 years, 19 of 63 patients had unplanned hospitalization for WHF, and 19 of 63 patients had cardiac death. Although atrial fibrillation was more often observed in patients with cardiac event (unplanned hospitalization for WHF and/or cardiac death), there was no significant difference in the other baseline clinical characteristics between the patients with and without cardiac event (Table 1). Patients

Table 1 Baseline clinical characteristics in the study patients with and without cardiac event (unplanned hospitalization for worsening heart failure and/or cardiac death)

|                          | With cardiac event (n = 28) | Without cardiac event (n = 35) | P-value |
|--------------------------|----------------------------|--------------------------------|---------|
| Follow-up time, years    | 7.3 ± 4.3                  | 10.2 ± 3.9                     | 0.0082  |
| Age, years               | 63 ± 14                    | 62 ± 13                        | 0.6264  |
| Male sex, %              | 86                         | 63                             | 0.0506  |
| Ischemic origin, %       | 39                         | 63                             | 0.0790  |
| Diabetes mellitus, %     | 18                         | 34                             | 0.1660  |
| Atrial fibrillation, %   | 39                         | 9                              | 0.0054  |
| Body mass index, kg/m²   | 22.7 ± 3.6                 | 23.6 ± 3.0                     | 0.2891  |
| Medication               |                            |                                |         |
| Diuretics                |                            |                                |         |
| Loop, %                  | 89                         | 71                             | 0.1190  |
| Spironolactone, %        | 71                         | 63                             | 0.5931  |
| Digitals, %              | 64                         | 54                             | 0.5963  |
| ACE inhibitor/ARB, %     | 86                         | 88                             | 0.9999  |
| l-Blocker*, %            | 79                         | 89                             | 0.3180  |
| NYHA functional class    | 2.2 ± 0.7                  | 2.1 ± 0.4                      | 0.3728  |
| Heart rate, beats/min    | 75 ± 14                    | 74 ± 10                        | 0.7840  |
| Systolic blood pressure, mmHg | 125 ± 20              | 130 ± 19                       | 0.3037  |

ACE, angiotensin-converting enzyme; ARB, angiotensin II type 1 receptor blocker; NYHA, New York Heart Association; WHF, worsening heart failure.

Data are presented as the mean value ± SD or percentage of patients *Use of β-blocker (carvedilol), as scored at the last follow-up visit.
with cardiac event had significantly larger left atrial dimensions, significantly higher MR grade, significantly lower serum sodium levels, significantly higher serum uric acid levels, and significantly higher plasma noradrenaline levels. Radionuclide RVEF was significantly lower, and WR was significantly higher in patients with than without cardiac event (Table 2).

### Prognostic analysis

Univariate and multivariate Cox proportional hazard analyses for unplanned hospitalization for WHF and cardiac death are shown in Table 3. In multivariate analysis, WR was the independent predictor of both endpoints. In addition, RVEF and New York Heart Association (NYHA) functional class predicted unplanned hospitalization for WHF, and LVEF and the presence of atrial fibrillation predicted cardiac death.

Kaplan–Meier analysis showed that patients with an abnormal WR had a significantly higher risk of unplanned hospitalization for WHF regardless of the presence or absence of a reduced RVEF (Figure 1), although this was not the case for cardiac death (Figure 2).

To better define the risk in individual patients, a predictive model was constructed based on three independent predictors of unplanned hospitalization for WHF identified by multivariate Cox analysis: the presence of abnormal WR, reduced RVEF, and NYHA functional class III/IV. Low-risk, intermediate-risk, and high-risk groups of unplanned hospitalization for WHF (none: 6%, one: 20%, two or three: 80%) or cardiac death (none: 6%, one: 33%, two or three: 53%) were identified according to the number of risk factors (Figure 3).

### Discussion

Increased sympathetic nerve activity in patients with CHF has been shown to be associated with a poor prognosis, and cardiac MIBG imaging has been introduced as a useful tool for the estimation of cardiac adrenergic nerve activity. Since the first report by Merlet et al. that showed the prognostic value of cardiac MIBG imaging in patients with CHF, the predictive value of MIBG imaging has been confirmed in several studies including ours. The present long-term, prospective, observational study expands on previous research by demonstrating that cardiac I-123 MIBG imaging can provide incremental value when it is combined with RV systolic dysfunction to predict clinical outcome in patients with CHF.

Although our result was in line with previous reports showing that RV systolic dysfunction is a predictor of poor prognosis in CHF patients, we did not observe a significant association between RV systolic dysfunction and cardiac mortality. This might be explained by the difference in the patients’ background. In our study, patients had mild to moderate symptoms of CHF, and only 15 patients (24%) were in NYHA class III/IV compared with 100% in the study by Meyer et al. Unlike in the study by De Groote et al., most of the study patients were enrolled before the beta-blocker era in our study. Moreover, the mean age of our study patients (62 years) was relatively higher than that of previous reports.

Our study was consistent with the report by Manrique et al. in that cardiac sympathetic dysfunction as assessed by cardiac MIBG imaging was an independent predictor of cardiac mortality, while RV systolic dysfunction was not. In addition to the results by Manrique et al., our study demonstrated that cardiac MIBG imaging provided incremental value when it was used along with RV systolic dysfunction to predict poor outcome in CHF patients, showing that a simple risk-stratification model based on the independent predictors of unplanned WHF hospitalization was useful not only for the prediction of heart failure admission but also for that of cardiac death.

Although RVEF measurement by radionuclide angiography has been considered the gold standard for RV systolic function, new RV systolic parameters, such as RVEF measured by magnetic resonance imaging or echocardiographic indices, are currently under evaluation. Further research is needed to identify the best index of RV systolic function and to
compare its prognostic value with that of cardiac MIBG imaging in CHF patients.

**Limitations of the study**

There are several limitations to this study. First, this is a single-centre study, and the number of the study subjects is small. Second, because we included only stable outpatients with mild to moderate heart failure symptoms, one should not generalize our results to patients with severe CHF. Third, we could not include several echocardiographic indices that have been shown to be predictive of clinical outcome of CHF patients in the analysis. Lastly, because most of the study patients were included in our placebo-controlled study where the efficacy of carvedilol or amlodipine was evaluated last century (T. Yamada et al., unpublished study, 1995 to 1999), no study patient received beta-blocker therapy at entry. As previously reported, results of cardiac MIBG imaging is influenced by heart failure medications. Therefore, caution should be made when generalizing our results to the recent patients with CHF.

**Table 3** Univariate and multivariate Cox proportional hazard analyses for the identification of patients at risk for unplanned hospitalization for worsening heart failure and cardiac death

|                      | Univariate analysis |          | Multivariate analysis |          |
|----------------------|---------------------|----------|-----------------------|----------|
|                      | P-value             | HR (95% CI) | P-value               | HR (95% CI)               |
| Cox proportional hazard model for unplanned hospitalization for worsening heart failure | | | | |
| WR                   | 0.0002              | 1.059 (1.028–1.092) | 0.0110              | 1.039 (1.009–1.070)       |
| LAD                  | 0.0015              | 1.089 (1.034–1.148) | —                    | —                     |
| RVEF                 | 0.0037              | 0.930 (0.886–0.976) | 0.0204              | 0.929 (0.873–0.988)       |
| Sodium               | 0.0178              | 0.838 (0.725–0.969) | —                    | —                     |
| NYHA functional class (III/IV) | 0.0228            | 2.900 (1.165–7.214) | 0.0495              | 2.739 (1.007–7.448)       |
| MR grade (≧grade 2) | 0.0242              | 3.102 (1.165–6.257) | —                    | —                     |
| Uric acid            | 0.0301              | 1.248 (1.023–1.522) | —                    | —                     |
| Atrial fibrillation  | 0.0423              | 2.675 (1.040–6.884) | —                    | —                     |
| Cox proportional hazard model for cardiac death | | | | |
| WR                   | 0.0004              | 1.057 (1.025–1.089) | 0.0118              | 1.047 (1.010–1.085)       |
| Atrial fibrillation  | 0.0015              | 4.349 (1.766–10.708) | 0.0293              | 2.999 (1.123–8.008)       |
| LAD                  | 0.0120              | 1.066 (1.014–1.120) | —                    | —                     |
| LVEF                 | 0.025               | 0.927 (0.874–0.984) | 0.0091              | 0.919 (0.862–0.979)       |
| Creatinine           | 0.0273              | 4.313 (1.186–15.692) | —                    | —                     |
| Uric acid            | 0.0297              | 1.305 (1.028–1.658) | —                    | —                     |

HR, hazard ratio; CI, confidence interval; LAD, left atrial dimension; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; RVEF, right ventricular ejection fraction; WR, washout rate of cardiac metaiodobenzylguanidine.

**Figure 1** Survival rates from unplanned heart failure hospitalization in patients with and without reduced RVEF. RVEF, right ventricular ejection fraction; CI, confidence interval; HR, hazard ratio; WR, washout rate of cardiac metaiodobenzylguanidine.
Conclusions

We demonstrated that in patients with CHF, cardiac MIBG imaging provided additional prognostic value when it was combined with RV systolic dysfunction. In addition, our result suggested that cardiac MIBG imaging was a more potent predictor of cardiac mortality in CHF patients compared with RV systolic dysfunction. Further studies are needed to compare prognostic value of cardiac MIBG imaging with that of RV systolic parameters and to better risk stratify the patients with CHF.

Conflict of interest

All authors declare that they have no conflict of interest.
References

1. Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2002;4:361–371.

2. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol 2011;8:30–41.

3. de Groot P, Millaire A, Fouquier-Hossein C, Nogue O, Marchandise X, Ducloix G, Lablanche JM. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. J Am Coll Cardiol 1998;32:948–954.

4. Manrique A, Bernard M, Hitzel A, Bauer F, de Groote P, Fertin M, Goeminne C, Petyt E, Meyer P, Filippatos GS, Ahmed MI, Merlet P, Valette H, Dubois-Rande JL, Menard JF, Sabatier R, Jacobson A, Vera P, Agostini D. Prognostic value of sympathetic innervation and cardiac asynchrony in dilated cardiomyopathy. Eur J Nucl Med Mol Imaging 2008;35:2074–2081.

5. Meyer P, Filippatos GS, Ahmed MI, Iskandrian AE, Bittner V, Perry GJ, White M, Alain IB, Mujib M, Dell’Italia LJ, Ahmed A. Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure. Circulation 2010;121:252–258.

6. de Groot P, Pertin M, Goeminne C, Petyt G, Peyrot S, Fouquier-Hossein C, Mouquet F, Bauters C, Lamblian N. Right ventricular systolic function for risk stratification in patients with stable left ventricular systolic dysfunction: comparison of radionuclide angiography and echocardiography parameters. Eur Heart J 2012;33:2672–2679.

7. Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, Bourguignon MH, Benvenuti C, Duval AM, Agostini D, Loisance D, Castaigne A, Syrota A. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471–477.

8. Yamada T, Shimonagata T, Fukunumi M, Kumagai K, Ogita H, Hirata A, Asai M, Makino N, Kikka H, Kusuoka H, Hori M, Hoki N. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzyguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol 2003;41:231–238.

9. Tamaki S, Yamada T, Okuyama Y, Morita T, Mano S, Tsukamoto Y, Masuda M, Okuda K, Iwasaki Y, Yasui T, Hori M, Fukunumi M. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol 2009;53:426–435.

10. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, Agostini D, Weiland F, Chandna H, Narula J, Tse D, Kong SL, Sanderson JE. Independent and incremental prognostic value of early mitral annulus velocity in patients with impaired left ventricular systolic function. J Am Coll Cardiol 2005;45:272–277.

11. Nakata T, Nakajima K, Yamashina S, Yamada T, Momose M, Kasama S, Matsui T, Matsu S, Travin MI, Jacobson AF. A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging 2013;6:772–784.

12. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971;285:1441–1446.

13. Little SH, Pirat B, Kumar R, Igo SR, McCulloch M, Hartley CJ, Xu J, Zoghbi WA. Three-dimensional color Doppler echocardiography for direct measurement of vena contracta area in mitral regurgitation: in vitro validation and clinical experience. JACC Cardiovasc Imaging 2008;1:695–704.

14. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819–823.

15. Schofer J, Spielmann R, Schuchert A, Weber K, Schluter M. Iodine-123 metaiodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988;12:1252–1258.

16. Wang M, Yip G, Yu CM, Zhang Q, Zhang Y, Tse D, Kong SL, Sanderson JE. Independent and incremental prognostic value of early mitral annulus velocity in patients with impaired left ventricular systolic function. J Am Coll Cardiol 2005;45:272–277.

17. Agostini D, Belin A, Amar MH, Darlas Y, Hamon M, Grollier G, Potier JC, Bouvard G. Improvement of cardiac neuronal function after carvedilol treatment in dilated cardiomyopathy: a 123I-MIBG scintigraphic study. J Nucl Med 2000;41:845–851.

18. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med 2002;43:1279–1285.